The latest publications and news on the ongoing activity at Sus Clinicals.
Translating Human Cancer Sequences Into Personalized Porcine Cancer Models
The global incidence of cancer is rapidly rising, and despite an improved understanding of cancer molecular biology, immune landscapes, and advancements in cytotoxic, biologic, and immunologic anti-cancer therapeutics, cancer remains a leading cause of death worldwide.
The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform
Cancer is a global epidemic causing more than 8 million annual deaths worldwide. The more than 13 million new cancer diagnoses made each year carry an economic burden of $290B. Cancer is expected to be the second leading cause of death in the United States in 2017. The American Cancer Society (ACS) estimates approximately 1,688,780 new cancer diagnoses will be made and 600,920 Americans will die from cancer.
The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery
The screening of potential therapeutic compounds using phenotypic drug discovery (PDD) is being embraced once again by researchers and pharmaceutical companies as an approach to enhance the development of new effective therapeutics. Before the genomics and molecular biology era and the consecutive emergence of targeted-drug discovery approaches, PDD was the most common platform used for drug discovery.
Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research
Cancer has recently surpassed cardiovascular diseases as the leading cause of death worldwide. The increasing cancer incidence combined with the emergence of improved therapeutic strategies has driven research into fields such as how the immune system Influences cancer development and progression. The term immunosurveillance has traditionally been used to describe how the immune system can protect the host from tumor development.